Market Overview

Oppenheimer Upgrades Agios Pharma On Expectations For First Drug Launch

Share:
Oppenheimer Upgrades Agios Pharma On Expectations For First Drug Launch

Oppenheimer has upgraded Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares to Outperform from Perform on higher expectations for its first drug launch and attractive valuation.

The company’s AG-221, developed along with partner Celgene Corporation (NASDAQ: CELG), is submitted for FDA approval for mutant isocitrate dehydrogenase-2 (IDH2) in advanced hematologic malignancies. The brokerage estimates that AG-221 could launch in the fourth quarter of 2017.

In addition, AG-120 is being studied in isocitrate dehydrogenase-1 (IDH1) mutant positive glioma and chondrosarcoma.

“We anticipate Agios will launch its first drug, AG-221, in partnership with Celgene Corporation, in 2017 and its second drug, AG-120, in 2018, two years sooner than we previously estimated,” analyst Leah Rush Cann wrote in a note.

Analyst's Estimations

The analyst estimates Agios’ total revenue will grow at a CAGR of 70.9 percent for the next six years, increasing to $1.47 billion in 2021.

Rush Cann also projects AG-221 could result in 2021 product sales of $1.4 billion and 2021 royalty income to Agios of nearly $172 million.

Further, the analyst anticipates AG-120 could result in 2021 product sales to Agios of $1.278 billion, significantly higher than prior estimate of $55 million.

At last check, shares of Agios were down 0.96 at $41.15. The analyst has a price target of $75.

Latest Ratings for AGIO

DateFirmActionFromTo
Feb 2020Cantor FitzgeraldReiteratesOverweight
Dec 2019BMO CapitalMaintainsOutperform
Dec 2019JP MorganMaintainsOverweight

View More Analyst Ratings for AGIO
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Upgrades Health Care Price Target FDA Best of Benzinga

 

Related Articles (CELG + AGIO)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
UALCFRADowngrades83.0
BRK/BCFRAMaintains235.0
SPNSNeedhamMaintains28.0
WLKBarclaysMaintains64.0
WBBarclaysMaintains48.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com